Review
Metabolic and Non-Metabolic Factors Determining Troglitazone Hepatotoxicity: A Review

https://doi.org/10.2133/dmpk.21.347Get rights and content

Summary:

Troglitazone (TGZ), a thiazolidinedione class of antidiabetic agent, causes serious idiosyncratic hepatotoxicity. TGZ is metabolized into reactive metabolites that covalently bind to cellular macromolecules, one of which is oxidation at the chromane ring, a unique structure of TGZ, and another involves oxidative cleavage of the thiazolidinedione ring, a structure common to less hepatotoxic antidiabetics, rosiglitazone and pioglitazone. TGZ is cytotoxic to HepG2 cells and rat and human hepatocytes. However, the role of the reactive metabolite on the TGZ toxicity is controversial, because there was no correlation of the generation of the reactive metabolites with susceptibility to the TGZ cytotoxicity, and chemical inhibitors of drug metabolizing enzymes could not protect the cells against the toxicity. Mitochondrial dysfunction, especially mitochondrial permeability transition, may be a pathophysiological event, which is mediated by TGZ itself and is a major non-metabolic factor. Other events such as apoptosis and PPARγ-dependent steatosis could be also mediated by TGZ, while inhibition of bile salt export pump, a cause of TGZ-induced cholestasis, may be caused by the TGZ sulfate. In conclusion, although the TGZ is biotransformed into chemically reactive metabolites, there is currently no potential evidence for involvement of the reactive metabolite in the TGZ-induced liver injury.

References (68)

  • K.G. Tolman et al.

    Hepatotoxicity of the thiazolidinediones

    Clin. Liver Dis.

    (2003)
  • S. Lloyd et al.

    Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors

    Chem. Biol. Interact.

    (2002)
  • J. Gao et al.

    Identification of in vitro protein biomarkers of idiosyncratic liver toxicity

    Toxicol. In Vitro

    (2004)
  • J.R. Soglia et al.

    The development of a higher throughput reactive intermediate screening assay incorporating micro-bore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent

    J. Pharm. Biomed. Anal.

    (2004)
  • M.A. Bae et al.

    Troglitazone but not rosiglitazone induces G1 cell cycle arrest and apoptosis in human and rat hepatoma cell lines

    Toxicol. Lett.

    (2003)
  • L.D. Kier et al.

    Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro

    Mutat. Res.

    (2004)
  • S. Shishido et al.

    Hydrogen peroxide overproduction in megamitochondria of troglitazone-treated human hepatocytes

    Hepatology

    (2003)
  • M.P. Bova et al.

    Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells

    Toxicol. Lett.

    (2005)
  • P. Bernardi

    The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death

    Biochim. Biophys. Acta

    (1996)
  • J.J. Lemasters et al.

    The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy

    Biochim. Biophys. Acta

    (1998)
  • Y. Masubuchi et al.

    Role of mitochondrial permeability transition in diclofenacinduced hepatocyte injury in rats

    Hepatology

    (2002)
  • Y. Masubuchi et al.

    Involvement of mitochondrial permeability transition in acetaminopheninduced liver injury in mice

    J. Hepatol.

    (2005)
  • Y. Masubuchi et al.

    Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones

    Toxicology

    (2006)
  • S. Green

    PPAR: a mediator of peroxisome proliferator action

    Mutat. Res.

    (1995)
  • M. Bedoucha et al.

    Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones

    J. Hepatol.

    (2001)
  • U.A. Boelsterli et al.

    Toxicological consequences of altered peroxisome proliferator-activated receptor γ (PPARγ) expression in the liver: insights from models of obesity and type 2 diabetes

    Biochem. Pharmacol.

    (2002)
  • R.E. Buckingham

    Thiazolidinediones: Pleiotropic drugs with potent anti-inflammatory properties for tissue protection

    Hepatol. Res.

    (2005)
  • K. Tomita et al.

    Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met

    Gastroenterology

    (2004)
  • S. Sigrist et al.

    Downregulation by troglitazone of hepatic tumor necrosis factor-alpha and interleukin-6 mRNA expression in a murine model of non-insulin-dependent diabetes

    Biochem. Pharmacol.

    (2000)
  • Y. Masubuchi et al.

    Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease

    Biochem. Biophys. Res. Commun.

    (2003)
  • C. Funk et al.

    Troglitazoneinduced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone sulfate

    Toxicology

    (2001)
  • P.B. Watkins et al.

    Hepatic dysfunction associated with troglitazone

    N. Engl. J. Med.

    (1998)
  • M.T. Smith

    Mechanisms of troglitazone hepatotoxicity

    Chem. Res. Toxicol.

    (2003)
  • M. Chojkier

    Troglitazone and liver injury: in search of answers

    Hepatology

    (2005)
  • Cited by (0)

    View full text